Lead Product(s): OLX101A
Therapeutic Area: Dermatology Product Name: OLX101A
Highest Development Status: Phase II Product Type: Large molecule
Deal Size: $37.2 million Upfront Cash: Undisclosed
Deal Type: Financing December 01, 2020
Capital will fund construction of RNA synthesis GMP facility in San Diego to advance the company’s core pipeline, including OLX101A for hypertrophic scars, OLX301A for age-related macular degeneration and OLX301D for subretinal fibrosis.